# EDGAR Filing Document

**Accession Number:** 0001393549
**File Stem:** 0001209191-23-016753
**Filing Date:** 2023-3
**Character Count:** 9147
**Document Hash:** a87ddaea93f2bea7dd51150b79e93ca0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001209191-23-016753.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0001209191-23-016753

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20230303

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230307

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Taylor Daphne
- **CENTRAL INDEX KEY:** 0001393549

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37746
- **FILM NUMBER:** 23713019

**MAIL ADDRESS:**
- **STREET 1:** 3303 MONTE VILLA PARKWAY
- **CITY:** BOTHELL
- **STATE:** WA
- **ZIP:** 98021

**FORMER NAME:**
- **FORMER CONFORMED NAME:** Taylor Daphne L
- **DATE OF NAME CHANGE:** 20070316
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Aptevo Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001671584
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 811567056
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2401 4TH AVE.
- **STREET 2:** SUITE 1050
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121
- **BUSINESS PHONE:** 206-838-0500

**MAIL ADDRESS:**
- **STREET 1:** 2401 4TH AVE.
- **STREET 2:** SUITE 1050
- **CITY:** SEATTLE
- **STATE:** WA
- **ZIP:** 98121

## Ex-24

```

POWER OF ATTORNEY

KNOW ALL BY THESE PRESENTS, that the undersigned hereby constitutes and appoints
SoYoung Kwon as his or her true and lawful attorney-in-fact to:

(1)	execute for and on behalf of the undersigned, in the undersigned's capacity
as an officer of Aptevo Therapeutics Inc. (the "Company"), Forms 3, 4, and 5 in
accordance with Section 16(a) of the Securities Exchange Act of 1934 and the
rules thereunder, and any other forms or reports the undersigned may be required
to file in connection with the undersigned's ownership, acquisition, or
disposition of securities of the Company;

(2)	do and perform any and all acts for and on behalf of the undersigned which
may be necessary or desirable to complete and execute any such Form 3, 4, or 5,
or other form or report, and timely file such form or report with the U.S.
Securities and Exchange Commission and any stock exchange or similar authority;
and

(3)	take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned, pursuant to this Power of Attorney, shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in his or
her discretion.

The undersigned hereby grants to such attorney-in-fact full power and authority
to do and perform each and every act and thing whatsoever requisite, necessary,
and proper to be done in the exercise of any of the rights and powers herein
granted, as fully to all intents and purposes as the undersigned might or could
do if personally present, with full power of substitution or revocation, hereby
ratifying and confirming all that such attorney-in-fact, or his substitute or
substitutes, shall lawfully do or cause to be done by virtue of this Power of
Attorney and the rights and powers herein granted.  The undersigned acknowledges
that no such attorney-in-fact, in serving in such capacity at the request of the
undersigned, is hereby assuming any of the undersigned's responsibilities to
comply with Section 13 and Section 16 of the Securities Exchange Act of 1934 and
the rules thereunder, as amended.

This Power of Attorney shall remain in full force and effect until revoked by
the undersigned in a signed writing delivered to the foregoing attorney-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 23rd day of January, 2023.

                                         /s/ Daphne Taylor

```

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Taylor Daphne<br><sub>(Last) (First) (Middle)</sub><br>C/O APTEVO THERAPEUTICS INC.<br>2401 4TH AVENUE, SUITE 1050<br><sub>(Street)</sub><br>SEATTLE, WA 98121<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Aptevo Therapeutics Inc. [ APVO ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2023-03-03 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_SVP, CFO_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 3840 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Unit | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 792 | <sup>(2)</sup> | D |  |
| Restricted Stock Unit | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 4750 | <sup>(2)</sup> | D |  |
| Restricted Stock Unit | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 13889 | <sup>(2)</sup> | D |  |
| Stock Option (right to buy) | <sup>(5)</sup> | 2030-02-18 | Common Stock | 2400 | $6.97 | D |  |
| Stock Option (right to buy) | <sup>(6)</sup> | 2030-07-27 | Common Stock | 514 | $8.56 | D |  |
| Stock Option (right to buy) | <sup>(6)</sup> | 2030-07-27 | Common Stock | 514 | $8.56 | D |  |
| Stock Option (right to buy) | <sup>(6)</sup> | 2030-07-27 | Common Stock | 516 | $8.56 | D |  |
| Stock Option (right to buy) | <sup>(6)</sup> | 2030-07-27 | Common Stock | 839 | $8.56 | D |  |
| Stock Option (right to buy) | <sup>(7)</sup> | 2031-01-29 | Common Stock | 7125 | $33.50 | D |  |
| Stock Option (right to buy) | <sup>(8)</sup> | 2032-03-04 | Common Stock | 4750 | $5.30 | D |  |

---

### Footnotes:

(1) The Restricted Stock Units ("RSUs") vest in three approximately equal annual installments beginning on January 29, 2022. The RSUs were granted on January 29, 2021. As of the date of this filing, all but 792 shares had vested.

(2) Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.

(3) The RSUs vest in three approximately equal annual installments beginning on March 4, 2023. The RSUs were granted on June 7, 2022.

(4) The RSUs vest in two approximately equal annual installments beginning the day immediately prior to the annual anniversary of the grant date.  The RSUs were granted on August 9, 2022.

(5) The option vests in three approximately equal annual installments beginning on February 18, 2021. The option was granted on February 18, 2020.

(6) The option vests in three approximately equal annual installments beginning on July 27, 2021. The option was granted on July 27, 2020.

(7) The option vests in three approximately equal annual installments beginning on January 29, 2022. The option was granted on January 29, 2021.

(8) The option vests in three approximately equal annual installments beginning on March 4, 2023. The option was granted on March 4, 2022.

**Signature:** /s/ SoYoung Kwon, Attorney-in-Fact  
**Date:** 2023-03-07

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**